Milestone Scientific Receives Notice of Allowance on Patent for CompuWave for Integration into CompuFlo(R) Epidural System

News & Press
January 16, 2020 8:30 am

Breakthrough technology provides further verification of epidural placement and real-time notification of obstruction or displacement of a catheter

Adds additional 20 years of patent protection around CompuFlo®

LIVINGSTON, NJ / January 16, 2020 / Milestone Scientific Inc. (NYSE American:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced it has received a Notice of Allowance for a key patent from the U.S. Patent and Trademark Office on its CompuWave technology, which is being integrated into the CompuFlo® Epidural System.

The Notice of Allowance relates to an apparatus that combines both objective pressure measurements and the detection of a pulsatile pressure waveform in a single system. Utilizing a high-resolution in-line pressure sensor in combination with the unique data processing within the CompuFlo System makes it capable of detecting both the in-situ pressure as well as the presence of a pulsatile pressure waveform. The pulsatile waveform is representative of the detection of pressures that are produced by the cardio-vascular system either directly or indirectly. This in turn can be used to aid in the identification of a needle or a catheter within an anatomic structure such as the epidural space. This same system can be used to aid in the determination of the patency of a catheter and to assist in determining if a catheter has been displaced during a procedure.

Mark Hochman, D.D.S., Inventor and Clinical Director for Milestone Scientific, commented, “This Notice of Allowance is an important advancement and line extension to our Dynamic Pressure Sensing (DPS®) technology that is currently used in the CompuFlo Epidural System. We believe the CompuWave technology represents a break-through for the CompuFlo Epidural System. This technology also has other medical applications, and we are planning to incorporate this innovative capability into future medical instruments for other indications as well.”

Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, stated, “We are constantly evolving and innovating our technology. This patent represents a significant achievement for the Company since it extends the IP protection around the CompuFlo instrument for another 20 years and provides not only additional confirmation of placement, but also verification during the procedure that the catheter has not been displaced. This advanced, patented technology further enhances our position at the forefront of the computerized injection market.”

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone’s computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology® is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website:

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2018. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

David Waldman or Natalya Rudman
Crescendo Communications, LLC
Tel: 212-671-1020

SOURCE: Milestone Scientific, Inc.

View source version on